Development and manufacturing HIV-1 fusion peptide carrier proteins for HIV vaccine clinical trail materials
Ended Awarded Last action
- Contract number
- HHSN26100049
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,765,471
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $4,765,471.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $857,704 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $3,907,767 |
About this award
The U.S. Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $4,765,471.00 cost-plus-fixed-fee delivery order contract to Leidos Biomedical Research, Inc. to develop and manufacture HIV-1 fusion peptide carrier proteins for use in an HIV vaccine clinical trial. This work is being performed at Leidos Biomedical's facility in Fort Detrick, Maryland. Leidos Biomedical Research, a subsidiary of Leidos Holdings, Inc., is a for-profit organization that provides a range of research, development, and production services to federal agencies, particularly in support of the NIH's biomedical research programs. This contract does not have a set-aside designation and was awarded on September 20, 2017 with a completion date of September 19, 2022.
Quick answers
Who was awarded contract HHSN26100049?
HHSN26100049 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2017.
How much is contract HHSN26100049 worth?
The government has obligated $4,765,471 on HHSN26100049.
Which agency awarded contract HHSN26100049?
National Cancer Institute (National Institutes of Health) awarded HHSN26100049, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100049 an order under another contract?
Yes. HHSN26100049 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100049 competed?
The extent of competition for HHSN26100049 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award